期刊文献+

原发性胆汁性肝硬化患者外周血临床免疫指标分析 被引量:2

下载PDF
导出
摘要 目的分析原发性胆汁性肝硬化(PBC)患者外周血细胞免疫及体液免疫临床指标。方法以流式细胞术分析51例PBC患者外周血细胞亚群,并同时检测血清中自身抗体、免疫球蛋白和补体成分。结果PBC组常规细胞亚群检测结果与健康对照、肝炎后肝硬化组相似,但PBC组中CD4CD45RA细胞比值均低于其他两个对照组,CD4CD45RO则高于对照组,在不同临床分期PBC患者间则无明显差异。51例PBC患者中抗线粒体抗体(AMA)阳性为100%,46例M2抗体为阳性(90.2%),抗核抗体(ANA)阳性率为82.4%,肝特异性自身抗体中抗- ASGPR阳性12例,SMA阳性者共有3例,未检出LKM-1,LC-1和SLA。PBC患者组血清免疫球蛋白IgG,IgM和IgA平均水平均高于肝炎后肝硬化组与健康对照组(P<0.05),不同临床分期患者间水平差异无显著性,3种亚类血清浓度升降呈一致性改变,而补体C3,C4水平在此3个实验组间未存在明显区别(P>0.05)。结论常规的细胞免疫检测如T细胞亚群分析对病情或疾病阶段的判断帮助不大,自身抗体与免疫球蛋白检测的应用目前主要限于辅助该病的诊断。
出处 《广东医学》 CAS CSCD 北大核心 2006年第7期984-986,共3页 Guangdong Medical Journal
基金 国家自然科学基金资助项目(编号:30300157)
  • 相关文献

参考文献8

  • 1HEATHCOTE E J.The American association for the study of liver diseases practice guidelines management of primary biliary cirrhosis[J].Hepatology,2000,31:1005-1013.
  • 2刘海英,范列英,沈芳,邓安梅,屠小卿,周晔,陈燕,仲人前.抗去唾液酸糖蛋白受体酶联免疫检测法的建立及临床初评[J].中华消化杂志,2004,24(2):98-101. 被引量:2
  • 3PRINCE M,AMANDA C,NEWMAN W,et al.Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years[J].Gastroenterology,2002,123:1044-1051.
  • 4姚定康,谢渭芬,陈伟忠,刘海英,屠小卿,范丽英.抗线粒体抗体及其分型对原发性胆汁性肝硬化的诊断价值[J].中华肝脏病杂志,2005,13(1):9-11. 被引量:42
  • 5HARADA K,ISSE K,TSUNEYAMA K,et al.Accumulating CD57CD3 natural killer T cells are related to intrahepatic bile duct lesions in primary biliary cirrhosis[J].Liver,2003,23(2):94-100.
  • 6TINMOUTH J,LEE M,WANLESS I R,et al.Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis[J].Liver,2002,22:228-234.
  • 7韩玉坤,魏振满,陈菊梅,张小峰,杨斌.原发性胆汁性肝硬化临床表现及自身抗体和血清学诊断意义[J].胃肠病学和肝病学杂志,2004,13(5):514-516. 被引量:6
  • 8LIU H Y,DENG A M,ZHONG R Q,et al.Correlation of Chlamydia pneumoniae infection with primary biliary cirrhosis:a study from serological evidence[J].World J Gastroenterol,2005,11 (26):4108-4110.

二级参考文献22

  • 1韩玉坤,张文瑾,陈菊梅,周华,王林杰.自身免疫性肝病临床与病理研究[J].中华肝脏病杂志,2001,9(S1):82-84. 被引量:11
  • 2Heathcote EJ.Management of primary biliary cirrhosis.The Ameri.can Association for the Study of Liver Discases practice guidelines.Hepatology,2000.31:1005-1013.
  • 3Kadokawa Y.Omagari K.Hazama H.et al.Evaluation of newly devcloped ELISA using "MESACUP-2 test mitochondrial M2"kit for the diagnosis of primary biliary cirrhosis.Clin Biochem,2003.36:203-210.
  • 4Fisiak R.Wiereinska-Drapalo A.Prokopowiez D.Antibodies against M-2 antigen in differential diagnosis of primary biliary cirrhosis.Pol Merkuriusz Lek.2000,8:373-375.
  • 5Metcalf JV.Mitchison HC.Palmer JM.et al.Natural history of early primary biliary cirrhosis.Lancet,1996.348:1399-1402.
  • 6Koizumi H.Onozuka Y.Shibata M.et al.Positive rate of antimitochondrial antibody in Japanese corporate workers.Rinshe Byori.2000.48:966-970.
  • 7Klein R.Pointner H.Zilly W.et al.Antimitochondrial antibody profiles in primary biliary cirrhosis distinguish at early stages between a benign and a progressive course prospective study on 200.patients followed follwed for 10 years.Liver,1997.17:119-128.
  • 8Lohse AW, Gerken G, Mohr H, et al. Relation between autoimmune liver diseases and viral hepatitis: clinical and serological characteristics in 859 patients. Z Gastroenterol,1995,33:527-533.
  • 9Yoshioka M, Mizuno M, Morisue Y, et al. Anti-asialoglycoprotein receptor autoantibodies, detected by a capture-immunoassay, are associated with autoimmune liver diseases. Acta Med Okayama,2002,56: 99-105.
  • 10Hajoui O, Debray D, Martin S, et al. Auto-antibodies to the asialoglycoprotein receptor in sera of children with autoimmune hepatitis. Eur J Pediatr,2000,159:310-313.

共引文献46

同被引文献13

  • 1闫惠平,庄辉,刘燕敏,冯霞,檀玉芬,刘妍,张欣,赵春惠.原发性胆汁性肝硬化患者的免疫学特点分析[J].中华肝脏病杂志,2005,13(1):12-16. 被引量:49
  • 2Dong Liang Wenfeng Ma Cuiwei Yao Huafeng Liu Xiaowen Chen.Imbalance of Interleukin 18 and Interleukin 18 Binding Protein in Patients with Lupus Nephritis[J].Cellular & Molecular Immunology,2006,3(4):303-306. 被引量:10
  • 3董生福,瞿涤.白细胞介素18在免疫应答中的作用[J].微生物与感染,2007,2(1):51-52. 被引量:3
  • 4Ishibashi H,Nakamura M,Shimoda S,Gershwin ME.T cell immunity and primary biliary cirrhosis[J].Autoimmun Rev,2003,2:19.
  • 5Heathcote E J.Management of primary biliary cirrhosis.The American Association for the Study of Liver Diseases practice guidelines[J].Hepatolgy,2000,31:1005.
  • 6Gershwin ME,Vierling JM,Manns MP.Liver Immunology:principles and practice[M].NY:Humana Press,2007.235-247.
  • 7Dickson ER,Grambsch PM,Fleming TR,Fisher LD,Langworthy A.Prognosis in primary biliary cirrhosis:model for decision making[J].Hepatology,1989,10:1.
  • 8Gershwin ME,Ansari AA,Mackay IR,et al.Primary biliary cirrhosis:an orchestrated immune response against epithelial cells[J].Immunol Rev,2000,174:210.
  • 9Dienes H P,Lohse A W,Gcrken G,et al.Bile duet epithelia as target cells in primary biliary cirrhosis and primary scleroaing cholangitis[J].Vimhows Arch,1997,431:119.
  • 10Klion FM,Fabry TL,Palmer M,Schaffner F.Prediction of survival of patients with primary biliary cirrhosis.Examination of the Mayo Clinic model on a group of patients with known endpoint[J].Gastroenterology,1992,102:310.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部